Consolidated Financial Results
for the Nine Months Ended November 30, 2021
[Japanese GAAP]
January 7, 2022
Company name: WELCIA HOLDINGS CO., LTD.
Stock exchange listing: Tokyo Stock Exchange
Code number: 3141
URL: https://www.welcia.co.jp/
Representative: Tadahisa Matsumoto, President and Representative Director
Contact: Norimasa Sato, Vice President, Director, Executive Officer and Chief Financial Officer
Phone: +81-3-5207-5878
Scheduled date of filing quarterly securities report: January 7, 2022
Scheduled date of commencing dividend payments: -
Availability of supplementary briefing material on quarterly financial results: Available
Schedule of quarterly financial results briefing session: Scheduled (for institutional investors)
(Amounts of less than one million yen are rounded down.)
1. Consolidated Financial Results for the Nine Months Ended November 30, 2021 (March 1, 2021 - November 30, 2021)
(1) Consolidated Operating Results (cumulative) | (% indicates changes from the previous corresponding period.) | |||||||||||
Net sales | Operating income | Ordinary income | Net income | |||||||||
attributable to | ||||||||||||
owners of parent | ||||||||||||
Nine months ended | Million yen | % | Million yen | % | Million yen | % | Million yen | % | ||||
November 30, 2021 | 756,403 | 6.5 | 29,815 | (9.6) | 32,943 | (6.1) | 20,208 | (6.8) | ||||
November 30, 2020 | 710,408 | 10.8 | 32,971 | 34.1 | 35,095 | 32.3 | 21,692 | 36.2 | ||||
(Note) Comprehensive | income: Nine months | ended November 30, | 2021: ¥20,184 million | [(7.6)%] | ||||||||
Nine months ended November 30, 2020: ¥21,842 million [37.2%] | ||||||||||||
Net income | Diluted net income | |||||||||||
per share | per share | |||||||||||
Nine months ended | Yen | Yen | ||||||||||
November 30, 2021 | 97.04 | 96.96 | ||||||||||
November 30, 2020 | 103.90 | 103.80 |
(Note) A two-for-one stock split of the Company's common stock was executed on September 1, 2020. "Net income per share" and "diluted net income per share" are calculated assuming that the stock split was executed at the beginning of the fiscal year ended February 28, 2021.
(2) Consolidated Financial Position
Total assets | Net assets | Equity ratio | |
Million yen | Million yen | % | |
As of November 30, 2021 | 436,913 | 196,161 | 44.6 |
As of February 28, 2021 | 435,685 | 180,351 | 41.2 |
(Reference) Equity: As of November 30, 2021: ¥194,991 million As of February 28, 2021: ¥179,490 million
2. Dividends
Annual dividends | ||||||||
1st quarter-end | 2nd quarter-end | 3rd quarter-end | Year-end | Total | ||||
Fiscal year ended | Yen | Yen | Yen | Yen | Yen | |||
- | 27.00 | - | 15.00 | - | ||||
February 28, 2021 | ||||||||
Fiscal year ending | - | 15.00 | - | |||||
February 28, 2022 | ||||||||
Fiscal year ending | ||||||||
February 28, 2022 | 15.00 | 30.00 | ||||||
(Forecast) | ||||||||
(Notes) 1. Revision to | the forecast for dividends announced most recently: None |
2. A two-for-one stock split of the Company's common stock was executed on September 1, 2020. The figure for the "2nd quarter-end" of the fiscal year ended February 28, 2021 is the actual dividend amount paid before the stock split was executed. The annual dividend for the fiscal year ended February 28, 2021 is not presented, because it is impossible to simply aggregate the amounts for each quarter-end due to the stock split. In pre-split terms, the year-end dividend would come to ¥30, making the annual dividend for the year ¥57.
3. Consolidated Financial Results Forecast for the Fiscal Year Ending February 28, 2022 (March 1, 2021 - February 28, 2022)
(% indicates changes from the previous corresponding period.)
Net income | Net income | ||||||||
Net sales | Operating income | Ordinary income | attributable to owners | ||||||
per share | |||||||||
of parent | |||||||||
Full year | Million yen | % | Million yen | % | Million yen | % | Million yen | % | Yen |
1,021,000 | 7.5 | 44,300 | 3.1 | 47,600 | 3.9 | 27,000 | (3.6) | 129.79 |
(Note) Revision to the financial results forecast announced most recently: None
* Notes:
(1) Changes in significant subsidiaries during the period under review: None (Changes in specified subsidiaries resulting in changes in scope of consolidation):
Newly included: - ( | ), Excluded: - ( | ) |
- Accounting methods adopted particularly for the preparation of quarterly consolidated financial statements: None
- Changes in accounting policies, changes in accounting estimates and retrospective restatement
- Changes in accounting policies due to the revision of accounting standards: None
- Changes in accounting policies other than 1) above: None
- Changes in accounting estimates: None
- Retrospective restatement: None
- Total number of issued and outstanding shares (common shares)
- Total number of issued and outstanding shares at the end of the period (including treasury stock):
November 30, 2021: | 209,633,676 shares |
February 28, 2021: | 209,633,676 shares |
2) Total number of treasury stock at the end of the period: | |
November 30, 2021: | 1,181,120 shares |
February 28, 2021: | 1,606,772 shares |
3) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year):
Nine months ended November 30, 2021: | 208,256,343 shares |
Nine months ended November 30, 2020: | 208,790,627 shares |
(Notes) 1. The number of shares of the Company held in the Employees' Stock Ownership ESOP Trust (February 28, 2021: 1,050,200 shares; November 30, 2021: 728,100 shares) and the number of shares of the Company held in the Directors' Remuneration BIP Trust (February 28, 2021: 502,238 shares; November 30, 2021: 440,442 shares) were included in the total number of treasury stock at the end of the period. The number of shares of the Company held in the Employees' Stock Ownership ESOP Trust and the Directors' Remuneration BIP Trust, was included in the number of treasury stock, which was to be deducted from the calculation of the average number of shares outstanding during the period (November 30, 2020: 787,822 shares; November 30, 2021: 1,356,609 shares).
2. A two-for-one stock split of the Company's common stock was executed on September 1, 2020. The figures for the "total number of issued and outstanding shares (common shares)" are calculated assuming that the stock split was executed at the beginning of the fiscal year ended February 28, 2021.
- These quarterly consolidated financial results are outside the scope of quarterly review by certified public accountants or an audit firm.
-
Explanation of the proper use of financial results forecast and other notes
The earnings forecasts and other forward-looking statements provided herein are based on information available to the Company and certain assumptions deemed reasonable, and the Company does not promise the achievement of those forecasts. Actual results may differ significantly from these forecasts due to a wide range of factors. For the assumptions underlying the forecasts and the notes on the use of the forecasts, please refer to "1. Qualitative Information on Quarterly Financial Results (3) Explanation of Consolidated Financial Results Forecast and Other Forward-looking Information" on page 4 of the attached document.
Table of Contents - Attachments | ||
1. Qualitative Information on Quarterly Financial Results ......................................................................... | 2 | |
(1) | Explanation of Operating Results ........................................................................................................ | 2 |
(2) | Explanation of Financial Position ....................................................................................................... | 4 |
(3) | Explanation of Consolidated Financial Results Forecast and Other Forward-lookingInformation | ....4 |
2. Quarterly Consolidated Financial Statements and Principal Notes ......................................................... | 5 | |
(1) | Quarterly Consolidated Balance Sheets .............................................................................................. | 5 |
(2) | Quarterly Consolidated Statements of Income and Comprehensive Income ...................................... | 7 |
Quarterly Consolidated Statements of Income | ||
Nine Months Ended November 30.............................................................................................. | 7 | |
Quarterly Consolidated Statements of Comprehensive Income | ||
Nine Months Ended November 30.............................................................................................. | 8 | |
(3) | Notes to Quarterly Consolidated Financial Statements ....................................................................... | 9 |
(Notes on going concern assumption) ............................................................................................ | 9 | |
(Notes in case of significant changes in shareholders' equity) ....................................................... | 9 | |
(Significant subsequent events) ...................................................................................................... | 9 |
1
1. Qualitative Information on Quarterly Financial Results
(1) Explanation of Operating Results
During the nine months ended November 30, 2021 (from March 1, 2021 to November 30, 2021), all the state of emergency and semi-emergency coronavirus measures issued to 27 prefectures due to the impact of the coronavirus disease (COVID-19) were lifted on September 30, 2021, and signs of a recovery resulting from gradually lifting the request for restriction on movement have been expected. However, the signs have been weak, and the Japanese economy continued to face difficulties. In addition, although the number of new cases of infection confirmed in Japan remains low, concerns associated with a potential resurgence of COVID-19 by a new variant have not been dispelled and uncertainty continues to prevail.
In the drugstore industry, the primary market for the Group's business, competition intensified, as the industry underwent reorganization even among the major players and entrants from other industries entered the market. Moreover, while demand continued for products to prevent infectious diseases as well as for foods, alcohol, and other products due to the ongoing restriction on movement to avoid the risk of infection, impacts of the restriction such as fewer people catching colds as a result of regularly wearing masks and washing their hands, and a drop in demand for cosmetics persist. Meanwhile, in the dispensing market, there are signs that the number of prescriptions will recover due to fewer people refraining from visiting doctors.
Under such circumstances, the Group made efforts to operate its business to provide products and services, while continuing to implement measures to prevent COVID-19 infections and thorough hygiene management. In terms of the sale of goods, the Cosmetics segment has not recovered the levels prior to COVID-19, while the Food Products segment reported a reactionary decline from a spike in special demand in the previous fiscal year. In terms of dispensing pharmacy sales, the number of prescriptions handled increased due primarily to the increase in the number of stores with dispensing pharmacies (1,797 stores as of November 30, 2021), despite the effects of the NHI drug price revision. Additionally, the Group managed to optimize selling, general and administrative expenses, mainly in terms of its labor costs by thoroughly managing store man-hours for optimization and improving store operational efficiency through the promotion of automatic ordering, while seeking to properly place pharmacists by promoting the addition of dispensing pharmacies to existing stores.
The Group also made efforts toward the improvement of business efficiency by carrying out an absorption- type merger, effective March 1, 2021, whereby Neo Pharma Co., Ltd. and Summit Co., Ltd., wholly-owned subsidiaries engaged in the dispensing business in Shikoku area mainly in Ehime Prefecture, were absorbed and WELCIA YAKKYOKU Co., Ltd., a consolidated subsidiary became the surviving company.
As for store openings and closures, the Group as a whole opened 115 stores and closed 21 stores, for a total of 2,312 stores Group-wide as of November 30, 2021. As of December 1, 2021, the Group converted Kabushiki Kaisha Pupule Himawari (132 stores), which operates stores mainly in Hiroshima Prefecture, into a subsidiary through the acquisition of shares.
2
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Welcia Holdings Co. Ltd. published this content on 14 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 January 2022 06:11:11 UTC.